Crossmark

Testosterone replacement therapy and cardiovascular risk

Crossref DOI link: https://doi.org/10.1038/s41569-019-0211-4

Published Online: 2019-05-23

Published Print: 2019-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gagliano-Jucá, Thiago http://orcid.org/0000-0002-2960-1059
Basaria, Shehzad http://orcid.org/0000-0003-1749-8549
License Information

Text and Data Mining valid from 2019-05-23

Version of Record valid from 2019-05-23
More Information

Article History

First Online: 23 May 2019

Competing interests

: S.B. has previously consulted for AbbVie, Eli Lilly and Regeneron Pharmaceuticals. T.G.-J. declares no competing interests.